Compare Pfizer with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs IPCA LABS - Comparison Results

PFIZER     Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER IPCA LABS PFIZER/
IPCA LABS
 
P/E (TTM) x 36.2 23.2 156.2% View Chart
P/BV x 6.1 4.4 137.7% View Chart
Dividend Yield % 0.6 0.3 204.7%  

Financials

 PFIZER   IPCA LABS
EQUITY SHARE DATA
    PFIZER
Mar-19
IPCA LABS
Mar-19
PFIZER/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs3,8401,042 368.5%   
Low Rs2,080590 352.5%   
Sales per share (Unadj.) Rs455.0298.6 152.4%  
Earnings per share (Unadj.) Rs93.835.0 267.9%  
Cash flow per share (Unadj.) Rs109.449.4 221.3%  
Dividends per share (Unadj.) Rs22.503.00 750.0%  
Dividend yield (eoy) %0.80.4 206.8%  
Book value per share (Unadj.) Rs658.2247.1 266.4%  
Shares outstanding (eoy) m45.75126.35 36.2%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x6.52.7 238.1%   
Avg P/E ratio x31.623.3 135.4%  
P/CF ratio (eoy) x27.116.5 163.9%  
Price / Book Value ratio x4.53.3 136.2%  
Dividend payout %24.08.6 279.9%   
Avg Mkt Cap Rs m135,420103,108 131.3%   
No. of employees `0002.613.4 19.6%   
Total wages/salary Rs m3,2387,874 41.1%   
Avg. sales/employee Rs Th7,911.42,807.0 281.8%   
Avg. wages/employee Rs Th1,230.9585.8 210.1%   
Avg. net profit/employee Rs Th1,630.7329.0 495.7%   
INCOME DATA
Net Sales Rs m20,81537,732 55.2%  
Other income Rs m1,674577 290.2%   
Total revenues Rs m22,48938,309 58.7%   
Gross profit Rs m5,7126,901 82.8%  
Depreciation Rs m7141,824 39.1%   
Interest Rs m73189 38.6%   
Profit before tax Rs m6,5995,465 120.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,3091,042 221.5%   
Profit after tax Rs m4,2914,422 97.0%  
Gross profit margin %27.418.3 150.0%  
Effective tax rate %35.019.1 183.4%   
Net profit margin %20.611.7 175.9%  
BALANCE SHEET DATA
Current assets Rs m27,16723,778 114.3%   
Current liabilities Rs m8,91710,975 81.2%   
Net working cap to sales %87.733.9 258.4%  
Current ratio x3.02.2 140.6%  
Inventory Days Days68104 65.4%  
Debtors Days Days3066 45.7%  
Net fixed assets Rs m8,86220,368 43.5%   
Share capital Rs m458253 181.0%   
"Free" reserves Rs m29,65630,971 95.8%   
Net worth Rs m30,11331,224 96.4%   
Long term debt Rs m251,409 1.8%   
Total assets Rs m39,40045,507 86.6%  
Interest coverage x91.530.0 305.5%   
Debt to equity ratio x00 1.8%  
Sales to assets ratio x0.50.8 63.7%   
Return on assets %11.110.1 109.3%  
Return on equity %14.214.2 100.6%  
Return on capital %22.117.3 127.8%  
Exports to sales %045.9 0.0%   
Imports to sales %016.6 0.0%   
Exports (fob) Rs mNA17,308 0.0%   
Imports (cif) Rs mNA6,266 0.0%   
Fx inflow Rs m42817,308 2.5%   
Fx outflow Rs m7866,266 12.5%   
Net fx Rs m-35811,042 -3.2%   
CASH FLOW
From Operations Rs m9784,923 19.9%  
From Investments Rs m351-1,563 -22.5%  
From Financial Activity Rs m-1,099-1,832 60.0%  
Net Cashflow Rs m2311,528 15.1%  

Share Holding

Indian Promoters % 0.0 45.9 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 11.4 65.8%  
FIIs % 4.9 25.3 19.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 17.4 136.2%  
Shareholders   85,207 36,892 231.0%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   CIPLA  NOVARTIS  ALEMBIC PHARMA  ORCHID PHARMA LTD  GSK PHARMA  

Compare PFIZER With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 229 Points Lower; Banking and Metal Stocks Witness Selling(Closing)

Indian share markets fell sharply during closing hours today amid weak global cues and disappointing domestic factory output data.

Related Views on News

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

PFIZER Announces Quarterly Results (2QFY20); Net Profit Up 61.0% (Quarterly Result Update)

Oct 29, 2019 | Updated on Oct 29, 2019

For the quarter ended September 2019, PFIZER has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 6 bn (up 9.1% YoY). Read on for a complete analysis of PFIZER's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Nov 13, 2019 03:37 PM

TRACK PFIZER

PFIZER - TTK HEALTHCARE COMPARISON

COMPARE PFIZER WITH

MARKET STATS